期刊文献+

血管内皮生长因子受体-2抑制剂高通量筛选模型的建立和应用 被引量:1

Establishment and Application of High Throughput Screening Model for Kinase Insert Domain Receptor
原文传递
导出
摘要 目的利用均相时间分辨荧光(HTRF)技术建立血管内皮生长因子受体-2抑制剂高通量药物筛选模型,从化合物样品库中寻找小分子抑制剂。方法使用20μL检测体系,384低容量白板,采用均相时间分辨荧光技术对反应体系中的酶活性进行荧光检测,进而评价待测样品的抑制活性。模型建立的体系优化包括如下实验步骤:酶浓度及反应时间优化,ATP和底物米氏常数测定,质控实验包括反应体系信噪比实验、抑制剂SU5416的IC50测定,Z'因子的测定。在建立稳定模型检测体系之后,对本中心化合物库提供的10 560个样品进行活性筛选,并对部分活性化合物进行IC50的测定。结果在血管内皮生长因子受体-2活性体系优化实验中求得血管内皮生长因子受体-2激酶最适反应酶浓度为0.10 ng.μL-1,最适反应时间为15min,ATP Km=0.75μmol.L-1,底物Km=94.90 nmol.L-1,信噪比底物:SA=2∶1,Z'值为0.85,阳性药IC50=1.03μmol.L-1。通过部分初筛活性样品进行复筛研究,得到3个活性化合物S2-14,S2-16、S2-38 IC50分别为1.01×10-4,6.04×10-5,7.23×10-6mol.L-1。结论利用均相时间分辨荧光技术成功建立了血管内皮生长因子受体-2激酶高通量筛选模型,并进行了一定量的定向筛选研究,发现了若干先导化合物。本实验体系方法可靠,结果稳定,可作为抗血管新生天然产物筛选体系进行应用推广。 OBJECTIVE To establish a KDR high throughput screening model with homogeneous time resolved fluorescence (HTRF) detection technology in order to screen small molecular KDR inhibitors from the compound library. METHODS A 20 μL assay system in 384-well low-volume white microplate was developed with HTRF based fluorescence detection system to determine the enzyme activity. The optimization steps consisted of the following experiments : enzyme concentration and incubation time optimiztion, ATP and substrate Km determination, quality control experiments including signal noise ratio inspection, the inhibitor SU5416 IC50 vali- dation, and Z' value calculation. After a stable assay system was accomplished, a HTS campaign was started with 10 560 samples from the compound library and the 1C50 of some compounds were determined. RESULTS The optimized KDR activity assay conditions were as follows: the kinase concentration was
出处 《中国药学杂志》 CAS CSCD 北大核心 2012年第11期894-898,共5页 Chinese Pharmaceutical Journal
基金 国家"重大新药创制"科技重大专项"十一五"计划(2009ZX09302-002) 教育部中央高校基本科研业务费专项资金资助(ZJ10036)
关键词 均相时间分辨荧光 血管内皮生长因子受体-2 血管新生 高通量筛选 homogeneous time resolved fluorescence kinase insert domain receptor, vascular endothelial growth factor keceptor 2 angiogenesis high throughput screening
  • 相关文献

参考文献1

二级参考文献6

共引文献3

同被引文献23

  • 1李旭桂,王广发,张俊艳,吴少瑜,徐伟,吴曙光,张嘉杰.用于蛋白酪氨酸激酶抑制剂高通量筛选的均相时间分辨荧光免疫方法的建立[J].南方医科大学学报,2009,29(8):1612-1614. 被引量:3
  • 2郑虎占,董泽宏,余靖.中药现代化研究与应用[M].第4卷.北京:学苑出版社,1998:3436.
  • 3CHEN YS, HO CC, CHENG KC,et al. Cureumin inhibited the arylaminesN-acetyhransferase activity, gene expression and DNA adduct formation in human lung cancer cells(A549) [ J]. Toxicol In Vitro ,2003,17 ( 3 ) :323 - 333.
  • 4BANERJI A,CHAKRABARTI J, AM1TR A,et al. Effect of cur- cumin on gelati-naseA (MMP-2) activity in B16F10 melanoma cells[J]. Cancer Letters,2004,211(2) :235 -242.
  • 5BERGERS G,BENJAMIN LE. Tumorigenesis and the angiogenic switch [ J ]. Nature Reviews Cancer, 2003,3 ( 6 ) :401 - 410.
  • 6SINGH AK,SIDHU GS, DEEPA T, et al. Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell [ J ]. Cancer Lett, 1996,107 ( 1 ) : 109 - 115.
  • 7YAMAMOTO Y, GAYNOR RB. Therapeutic potential of inhibi- tion of the NF-kappaB pathway in the treatment of inflammation and cancer[ J ]. J Clin Invest,2001,107 (2) : 135 - 142.
  • 8SHISHODIA S, AMIN HM, LAI R, et al. Curcumin ( diferuloyl- methane) inhibits constitutive NF-kappaB activation, induces G1/Sarrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma [J]. Biochem Pharmacol, 2005,70 ( 5 ) : 700 - 710.
  • 9PARK SY,K1M DS. Discovery of natural products from Cureuma longa that protect cells from beta-amyloid insuh:a drug discovery effort against Alzheimer's disease [ J ]. Nat Prod, 2002,65 ( 9 ) : 1227 - 1231.
  • 10KIUCHI F, IWAKAMI S, SHIBUYA M, et al, Inhibition of pros- tagland in and leukotriene biosynthesis by gingerols and diaryl- heptanoids [ J ]. Chem Pharm Bull, 1992,40 ( 2 ) : 387 - 391.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部